We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info . X close

Spatial Genomics & Transcriptomics Market: Growth, Size, Share, and Trends

Report Code BT 7790
Published in Dec, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Spatial Genomics & Transcriptomics Market by Product (Instruments, Consumables, Services), Technique (Transcriptomics (IHC, ISH), Genomics (LCM), Service Type (Sample Prep, Sequencing), Application (Translation Research (Cancer)) - Global Forecast to 2029

Overview

The global spatial genomics & transcriptomics market, valued at US$532.7 million in 2023, is forecasted to grow at a robust CAGR of 12.4%, reaching US$554.5 million in 2024 and an impressive US$995.7 million by 2029. Market growth is attributed to factors such as increasing adoption of spatial genomics and transcriptomics in drug discovery and development, increasing pharmaceutical R&D investments and public-private funding, introduction of technologically advanced instruments for spatial genomics analysis, and the introduction of novel products are driving the growth of the spatial genomics & transcriptomics market. However, the faces several challenges due to high initial capital investments and technical complexity and expertise gap.

Spatial Genomics & Transcriptomics Market

Attractive Opportunities in the Spatial Genomics & Transcriptomics Market

North America

Growth in the North American spatial genomics & transcriptomics market can be attributed to the presence of well-established and emerging biotechnology companies, growing emphasis on personalized medicines, and rising government funding.

The increasing adoption of spatial genomics and transcriptomics in drug discovery and development and increasing pharmaceutical R&D investments and public-private funding are driving the market growth.

Increasing use of spatial omics for biomarker identification and increasing demand for precision medicines and targeted drug development present significant growth opportunities for this market.

High initial capital investments & maintenance costs and technical complexity and expertise gap limit the growth of this market.

Globally, North America is the largest market for gene spatial genomics & transcriptomics and this trend is expected to continue during the forecast period.

Global Spatial Genomics & Transcriptomics Market Dynamics

DRIVER: Rising pharmaceutical R&D expenditures and public-private financing

The pharmaceutical R&D industry has traditionally been capital-intensive because of long development periods and approval cycles. Governments view R&D as an important investment for a country's development, global competitiveness, and social good. As such, R&D spending and financing have been constantly rising. Increasing investments in spatial genomics and transcriptomics by market players and research institutes, along with the support of investors and venture capitalists, are expected to propel the use of innovative technologies, such as spatial genomics. With the growing need for early diagnosis and remedial treatment of life-threatening diseases, there has been an increase in the number of R&D programs to develop innovative products and technologies to curb such diseases; this has guaranteed consistent private investments, government funding, and grants within the spatial genomics and transcriptomics sectors. For example, Moleculent AB in June 2024 reported closing of the oversubscribed USD 25.0 million Series A financing to drive spatial mapping of cell-cell communication. In January 2023, Nature's Array, a startup in the spatial transcriptomics area, received seed funding amounting to USD 10.0 million. The funds will aid the company to advance its novel method for dissecting tissue architecture and gene expression and develop research in different areas, including cancer. In August 2022, Revolutionary Genomics has raised USD 50.0 million in funding for its Series A in developing spatial genomics technology. This funding provided more depth in understanding diseases and supported the efforts of finding drugs while exploiting the value of spatial data within genomic studies. In March 2022, Spatial Genomics Inc. concentrated in spatial genomics and secured USD 30.0 million in a Series A round. The proceeds were to be used in expansion of its capabilities in gene expression and tissue architecture studying, which are critical in understanding complex biological systems and diseases. In February 2022, Fulgent Genetics announced a strategic investment in Spatial Genomics, Inc. The company develops sequential fluorescence in situ hybridization (seqFlSH) technology. Fulgent Genetics invested up to USD 40 million to lead Spatial genomics' Series A financing, which totals approximately USD 56 million and includes investments by 12 West Capital and other investors.

RESTRAINT: Highly expensive capital investments and service charges at the outset

One of the most significant limitations for the demand of spatial genomics and transcriptomics in small and medium -sized research institutes has been the highly expensive nature of capital investment to get technologically advanced systems along with the software. Improved instruments are much costlier because their development process is pretty expensive. For example, during 2024, for an Illumina Nova Seq system. The cost of a NextSeq 500 instrument from Illumina is NUSD 125,000. The high investment cost has led to the lower adoption of transcriptomic technologies in small and medium-sized research labs. Researchers are hesitant to invest in new technologies, especially given the limited evidence of measurable returns on investment. In addition, the outcome of the studies may not always be as expected, leading to unsatisfactory results or process re-runs, thus raising the general cost of the study. Companies use available structural data and trial-and-error approaches to identify the compounds that activate or inhibit targets. All procedures require significant laboratory hours, thus making the cost of testing per sample high. Such expensive costs of equipment and reagents make it difficult for developing countries to venture into the field of transcriptomics. The costs associated with this technology are too high, which has led to the lower-than-expected adoption of transcriptomic technologies worldwide. Instrument maintenance is costly and includes spares, chemicals, consumables, and timely servicing. Highly trained manpower is also needed for using these instruments. Though the cost of transcriptomic technologies is coming down, it is still pretty high for small and medium-sized research laboratories. The huge investment required in the preliminary phase acts as a restraining factor and limits the deployment of transcriptomic technologies in the market. Growth in the investment in research fund and government support towards research on transcriptomics might address this in the future years.

 

OPPORTUNITY: Increasing use of spatial omics for biomarker identification

Biomarker identification and clinical applications have simplified drug discovery and development procedures in evaluating drug toxicity and efficacy. Besides, biomarkers for diseases such as cancer, CVDs, and neurological diseases help better understand the disease pathway and progression. The discovery of new biomarkers in diagnosing various diseases, especially cancer diagnosis, has brought revolutionary medical changes. Furthermore, continuous developments in sequencing technologies have increased the efficiency of biomarkers in disease detection and their utilization in disease diagnoses.

The increasing demand for biomarkers is expected to boost the transcriptomics technologies market. The substantial addressable market for biomarkers and the growing applications of transcriptomics in biomarker discovery are expected to provide significant growth opportunities for the overall market for the next few years. According to the International Agency for Research on Cancer (IARC), there were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The rising prevalence of cancer has compelled researchers to focus on identifying markers that distinguish between indolent and aggressive cancers.

Multiplex spatial tissue analysis (MSTA) is an emerging technique to address the needs of researchers intending to interrogate the tumor microenvironment at unprecedented levels of detail and granularity. MSTA refers to methodologies for assessing multiple biomarkers (protein and nucleic acid markers) at specific locations within a tissue sample. With the expansion of various novel approaches, it is now possible to assess from dozens up to >1,000 RNA and protein markers (at least in regions of interest) simultaneously while preserving (some degree of) spatial context.

CHALLENGES: Dearth of skilled professionals

Spatial genomics and transcriptomics are new areas of omics research. The global development of spatial transcriptomics research has been concentrated in the US and other developed countries in Europe. Moreover, even in these countries, the scope of spatial transcriptomics research is relatively small compared to other areas of omics research. Due to this, only limited research expertise is available in this field. Transcriptome analysis comprises sophisticated methods to study biological entities within a laboratory setup. It involves labor-intensive techniques and skilled professionals such as researchers and technicians performing experiments, setting up and running tests and experiments, making observations, obtaining results, and analyzing data. Lack of knowledge regarding the underlying scientific principles and the right choice of technique may result in several direct and indirect expenses, increasing the workload and time pressure on researchers and service providers. Thus, there is a need for highly skilled personnel for method development, validation, operation, and troubleshooting activities. CodeWizardsHQ estimates that, almost 4x quicker than non-STEM professions, STEM employment are expected to rise 10.8% between 2022 and 2032. By 2025, the US needs Ell around 3.5 million jobs, but a skills shortage would cause 2 million of them to be unmet. Moreover, according to the US Bureau of Labor Statistics, the last decade has seen considerable concern regarding a shortage of STEM workers to meet market demands. Although the demand for STEM skills rose by 20% from 2009 to 2015, the US Bureau of Labor Statistics mentions a shortage of skilled medical professionals in medical research, pharmaceuticals, and sciences. As the early adopters of newer technologies in life sciences, European countries face similar challenges due to a shortage of graduates in STEM fields. The share of STEM graduates has fallen from 24.8% to 22.7% in the last decade. The lack of clarity around the outcomes of transcriptomic research and the high equipment cost have led to the lower adoption of transcriptomic technologies, thereby limiting the spread of technical knowledge related to transcriptomics research.

Global Spatial Genomics & Transcriptomics Market Ecosystem Analysis

Raw material suppliers, product and service providers, end users and regulatory bodies make up the varied network of components in the spatial genomics and transcriptomics market ecosystem. By working together, these researchers speed and implement spatial genomics technologies, therefore promoting innovation and accelerating the transfer from the lab to useful applications in individualized medicine and beyond. Suppliers of raw materials in the spatial genomics and transcriptomics market facilitate product development and manufacture by the provision of essential components, including high-quality reagents, enzymes, primers, and other consumables critical for genomic assays and spatial analytic technologies.

The spatial genomics and transcriptomic ecosystem depends much on commercial enterprises offering products and services. Among them are big companies as 10x Genomics, Illumina, and NanoString Technologies. Such companies create and produce analytical tools, spatial transcriptomics tools, and novel sequencing technologies. Those people who really apply the tools of spatial genomics and transcriptomics in another field represent the key component. Among these are research and academic institutions, CROs and CDMOs, biotechnology and pharmaceutical companies.

Regulatory agencies guarantee that products derived from spatial genomics and transcriptomics are safe and useful in illness treatment. For instance, drugs derived from genetic research and diagnostic tests are approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Spatial Genomics & Transcriptomics Market
 

In the spatial genomics and transcriptomics market in 2023 the product segment held the largest share of offering segment.

Spatial genomics and transcriptomics market is divided by Segments- products and services. Products will have the highest share in 2023. The part of the spatial genomics and transcriptomics market is instruments & software as well as consumables. Imaging devices, sequencing tools, and data analysis software in the section Tools in Instruments & Software help to gather and interpret spatially resolved genomic data. The emergence of this field is clarified by the increasing need in research for high-resolution spatial gene and protein expression data. Key drivers influencing the market expansion include consumables and the expanding uses of spatial genomics and transcriptomics in drug research and development as well as in biomarker identification. Moreover, different software users—especially for spatial analysis and new product launch—are investing more, which facilitates the growth of this market. The consumables category in the spatial genomics and transcriptomics market encompasses essential reagents, gene panels, assay kits, and additional supplies for sample preparation and data processing. NanoString Technologies, Inc. (US) provides a range of consumables for its GeoMx and nCounter platforms, featuring specialized panels for oncology, neuroscience, cardiovascular disease, and immunology research. In August 2022, Massachusetts General Hospital (US) employed GeoMx consumables alongside its Human Whole Transcriptome Atlas to delineate pancreatic cancer at the molecular level. The demand for improved reproducibility and high-quality data gathering to enhance spatial genomics research in oncology and precision medicine is propelling the consumables market.

In 2023, transcriptomics technique accounted for the highest share in the market.

Based on technique, segmentation of the spatial genomics and transcriptomics market is achieved by spatial transcriptomics and spatial genomics approaches. Driven by increasing acceptance of in situ sequencing technologies and increasingly broad applications in disease research, the segment of spatial transcriptomics held the largest proportion of spatial genomics and transcriptomics market in 2023. Spatial transcriptomics is further analyzed across immunohistochemistry (IBC), immunofluorescence (IF), microscopy-based RNA imaging, In-situ hybridization (ISH), laser Capture microdissection (LCM), RNA sequencing and other transcriptomics techniques. Using spatial transcriptomics, one maps gene expression within the spatial context of a tissue. Combining histology and molecular data indicates how genes are expressed in certain tissue countries or regions, therefore guiding understanding of cellular architecture, function, and disease progression. Applications of spatial transcriptomics are many in clinical and scientific spheres. In cancer research, it aids in the identification of tumor microenvironments and cell-to---cell interactions, so guiding focused therapy. In neuroscience, it guides brain Country/Regions toward comprehension of intricate neural networks. It also helps identify biomarkers, advances diagnostics, and creates individualized treatments for many ailments.

The spatial genomics and transcriptomics market in 2023 was dominated by North America.

Six main regions are covered in the spatial genomics & transcriptomics market: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. While Europe is the second biggest regional market for spatial genomics & transcriptomics in 2023, North America is the largest. Together with key players in the spatial genomics and transcriptomics market, increasing focus on individualized medicine, and government financing, North America's huge share can be ascribed to the existence of established and developing biotechnology enterprises.

In order to broaden their product offers, businesses have been concentrating on mergers and acquisitions. In order to develop and market new products, as well as to further genetics research, a number of the most successful businesses in this region have acquired smaller businesses that were already producing related product lines. For example, on October 10, 2023, 10x genomes made the announcement that it had purchased Basepaws (US), a company in the United States that provides technologically enhanced health diagnostics based on genomes. The acquisition was estimated to be worth around 100.0 million USD dollars.

Nonetheless, The Asia Pacific is projected to be the fastest-growing segment of the market defined by increasing government efforts to meet rising healthcare needs, growing government investment in biotechnology, growing demand of precision medicine, rising healthcare expenditure, growing R&D expansion in important markets including India, China, and Japan, and the favorable regulatory environment in the region.

HIGHEST CAGR MARKET IN 2024
US FASTEST GROWING MARKET IN THE REGION
Spatial Genomics & Transcriptomics Market

Recent Developments of Spatial Genomics & Transcriptomics Market

  • In October 2024, 10x Genomics and Beckman Coulter Life Sciences collaborated to improve automation for single-cell assay operations.
  • In October 2024, Illumina, Inc. announced the launch of MiSeq ilOO sequencing equipment. These systems offer unrivaled benchtop speed and simplicity, advancing next-generation sequencing (NGS) in labs.
  • In September 2024, Bio-Techne announced that one of its spatial biology brands, Lunaphore, is partnering with Discovery Life Sciences (Discovery) to add Lunaphore COMET, a best-in-class spatial biology platform, to Discovery's global suite of biospecimen products and specialty lab services supporting customers with clinical research.
  • In June 2024, Bio-Rad Laboratories, Inc. launched a ddSEQ Single-Cell 3' RNA-Seq Kit and complementary Omnition analysis software for single-cell transcriptome and gene expression research.

Key Market Players

Want to explore hidden markets that can drive new revenue in Spatial Genomics & Transcriptomics Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD Million)
Segments covered Offering, Technique, Application, Type (Service), End User (Product), End User (Service).
Geographies covered North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

 

Key Questions Addressed by the Report

Who are the key players in the spatial genomics & transcriptomics market?
Key players in the spatial genomics & transcriptomics market include NanoString Technologies, Inc. (Bruker Spatial Biology, Inc.) (US), 10x Genomics (US), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), Bio-Techne (US), Standard BioTools (US), and Akoya Biosciences, Inc. (US).
Which offering segment dominates the spatial genomics & transcriptomics market?
The product segment dominated the spatial genomics & transcriptomics market by offering, its share can be attributed due to the increasing demand for high-resolution spatial gene and protein expression data in research.
Which technique segment dominated the spatial genomics & transcriptomics market?
In 2023, spatial transcriptomics dominated the spatial genomics & transcriptomics market by technique, majorly due to the increasing adoption rate of in situ sequencing techniques and broader applications in disease research.
Which type (service) segment held the largest market share of the spatial genomics & transcriptomics market?
In 2023, the sequencing & analysis services segment held the largest market share of the spatial genomics & transcriptomics market by type (service), this can be attributed to the rising demand for precise gene expression profiling in disease research and drug development.
Which application segment dominated the spatial genomics & transcriptomics market?
In 2023, translational research dominated the spatial genomics & transcriptomics market by application, majorly due to increasing funding for research in spatial genomics and transcriptomics.
Which end user (product) segment dominated the spatial genomics & transcriptomics market?
In 2023, academic & research institutes dominated the spatial genomics & transcriptomics market by end user (product), majorly due to increasing need of precise cellular insights in scientific research.
Which end user (service) segment dominated the spatial genomics & transcriptomics market?
In 2023, academic & research institutes dominated the spatial genomics & transcriptomics market by end user (service), majorly due to increasing need for tools to map cellular environments and study disease mechanisms.
What is the market size of spatial genomics & transcriptomics market?
The spatial genomics & transcriptomics market is expected to grow to USD 995.7 million by 2029 from USD 554.5 million in 2024, at a CAGR of 12.4%

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Spatial Genomics & Transcriptomics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
1
RESEARCH METHODOLOGY
45
EXECUTIVE SUMMARY
78
PREMIUM INSIGHTS
92
MARKET OVERVIEW
116
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    RESTRAINTS
    OPPORTUNITIES
    CHALLENGES
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
  • 5.4 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
    AVERAGE SELLING PRICE OF PRODUCTS, BY REGION
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - IN SITU SEQUENCING
    - IN SITU HYBRIDIZATION (ISH)
    - SINGLE-CELL RNA SEQUENCING (SCRNA-SEQ)
    COMPLEMENTARY TECHNOLOGIES
    - MULTIPLEXED ION BEAM IMAGING (MIBI)
    - SPATIAL HEATMAPS
    - DIFFERENTIAL GENE EXPRESSION (DGE) ANALYSIS
    ADJACENT TECHNOLOGIES
    - MULTI-OMICS
    - METABOLOMICS
    - SINGLE-CELL ANALYSIS
  • 5.9 PATENT ANALYSIS
  • 5.10 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.11 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
    REGULATORY FRAMEWORK
  • 5.12 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITION RIVALRY
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA FOR END USERS
  • 5.14 INVESTMENT AND FUNDING SCENARIO
  • 5.15 IMPACT OF AI/ GEN AI ON SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET
SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY OFFERING, 2022-2029
156
  • 6.1 INTRODUCTION
  • 6.2 PRODUCT
    INSTRUMENTS & SOFTWARE
    CONSUMABLES
  • 6.3 SERVICES
SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCT MARKET, BY TEHNIQUE, 2022-2027
189
  • 7.1 INTRODUCTION
  • 7.2 SPATIAL TRANSCRIPTOMICS
    IMMUNOHISTOCHEMISTRY (IHC)
    IMMUNOFLUORESCENCE (IF)
    MICROSCOPY-BASED RNA IMAGING
    IN SITU HYBRIDIZATION (ISH)
    LASER CAPTURE MICRODISSECTION (LCM)
    RNA SEQUENCING
    - IN SITU RNA SEQUENCING
    - SINGLE-CELL RNA (SC-RNA) SEQUENCING
    - OTHER RNA SEQUENCING (IF ANY)
    OTHERS TRANSCRIPTOMICS TECHNIQUES
  • 7.3 SPATIAL GENOMICS
    IN SITU HYBRIDIZATION (ISH)
    LASER CAPTURE MICRODISSECTION (LCM)
    GENOMIC SEQUENCING
    - MICRODISSECTION-BASED SEQUENCING
    - CHROMATIN ACCESSIBILITY SEQUENCING (ATAC-SEQ)
    - OTHER SEQUENCING TECHNIQUES (IF ANY)
    OTHER GENOMICS TECHNIQUES
SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICE MARKET, BY TYPE, 2022-2029
205
  • 8.1 INTRODUCTION
  • 8.2 SAMPLE PREPARATION SERVICES
  • 8.3 SEQUENCING & ANALYTICAL SERVICES
  • 8.4 DATA VISUALIZATION & ANALYSIS SERVICES
SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY APPLICATION, 2022-2029
256
  • 9.1 INTRODUCTION
  • 9.2 TRANSLATIONAL RESEARCH
    CANCER
    IMMUNOLOGY
    NEUROSCIENCE
    INFECTIOUS DISEASES
    OTHER DISEASES
  • 9.3 DRUG DISCOVERY & DEVELOPMENT
SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCT MARKET, BY END USER, 2022-2029
289
  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 10.3 ACADEMIC & RESEARCH INSTITUTES
  • 10.4 CROS & CDMOS
  • 10.5 CLINICAL DIAGNOSTIC LABORATORIES
SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICE MARKET, BY END USER, 2022-2029
303
  • 11.1 INTRODUCTION
  • 11.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 11.3 ACADEMIC & RESEARCH INSTITUTES
  • 11.4 OTHER END USERS (SMALL-SCALE CROS & CDMOS, CLINICAL DIAGNOSTIC LABORATORIES)
SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY REGION, 2022-2029
356
  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    CANADA
  • 12.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    UK
    FRANCE
    ITALY
    SPAIN
    REST OF EUROPE
  • 12.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    JAPAN
    INDIA
    SOUTH KOREA
    AUSTRALIA
    REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    MEXICO
    REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 12.7 AFRICA
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
378
  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
  • 13.3 REVENUE SHARE ANALYSIS
  • 13.4 MARKET SHARE ANALYSIS
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - COMPANY FOOTPRINT
    - REGION FOOTPRINT
    - OFFERING FOOTPRINT
    - TECHNIQUE FOOTPRINT
    - APPLICATION FOOTPRINT
  • 13.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    - DETAILED LIST OF KEY STARTUPS/SMES
    - COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • 13.7 COMPETITIVE SCENARIO
    DEALS
    OTHER DEVELOPMENTS
  • 13.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 13.9 VENDOR VALUATION AND FINANCIAL METRICS
COMPANY PROFILES*
390
  • 14.1 KEY PLAYERS
    NANOSTRING TECHNOLOGIES, INC.
    10X GENOMICS
    ILLUMINA, INC.
    BIO-RAD LABORATORIES, INC.
    BIO-TECHNE
    STANDARD BIOTOOLS
    VISIOPHARM A/S
    AKOYA BIOSCIENCES, INC.
    DANAHER CORPORATION
    NATERA, INC.
    REVVITY
    SEVEN BRIDGES GENOMICS
    S2 GENOMICS, INC.
    CANTATA BIO
    VIZGEN INC.
  • 14.2 OTHER PLAYERS
    BIOSPYDER TECHNOLOGIES, INC.
    REBUS BIOSYSTEMS, INC.
    MILTENYI BIOTEC, INC.
    RARECYTE, INC.
    ULTIVUE, INC.
    LUNAPHORE TECHNOLOGIES SA
    IONPATH, INC.
    VISIKOL, INC.
    SINGULAR GENOMICS SYSTEMS, INC.
    VERACYTE, INC.
APPENDIX
404
  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 15.3 AVAILABLE CUSTOMIZATIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS

This study on the spatial genomics & transcriptomics market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the spatial genomics & transcriptomics market using several research strategies, the size of the final market was obtained by triangulating data from primary research.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as World Health Organization (WHO), National Institutes of Health (NIH), Organisation for Economic Co-operation and Development (OECD), International Agency for Research on Cancer (IARC), Research!America, Genome Canada, GenomeWeb, South African Medical Research Council (SAMRC), Wellcome Sanger Institute, Genome Research Limited, Labiotech.eu, R&D World Magazine, India Brand Equity Foundation (IBEF), Biotechnology Innovation Organization (BIO), National Center for Biotechnology Information (NCBI), BioPharm International, EvaluatePharma, ScienceDirect, Eurostat. Secondary sources include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global spatial genomics & transcriptomics market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global spatial genomics & transcriptomics market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing gene editing products and services; experts from the demand side, such as personnel from pharmaceutical & biotechnology companies, Academic & research institutes, clinical diagnostic laboratories, and CROs & CDMOs. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Spatial Genomics & Transcriptomics Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the spatial genomics & transcriptomics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the spatial genomics & transcriptomics market business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Top-down Approach

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Spatial Genomics & Transcriptomics Market

Data Triangulation

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

The spatial genomics & transcriptomics market, as covered within the scope of this report, includes products, technologies, and services that facilitate spatial genomics & transcriptomics across various applications. Spatial genomics and transcriptomics are pioneering technologies that allow scientists to measure the gene activity in a tissue sample and map the site of the activity. Spatial transcriptomics helps spatially resolve RNA-seq data and all mRNAs in individual tissue sections. The technology is presently used in translational research and can be used in clinical diagnosis in the future. Spatial genomics also helps map gene expressions across human tissues.

Stakeholders

  • Manufacturers and distributors of spatial genomics and transcriptomics products
  • Spatial genomics and transcriptomics service providers
  • Pharmaceutical and biotechnology companies
  • Contract research organizations (CROs)
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Market research and consulting firms
  • R&D centers
  • Researchers and scientists
  • Academic & research institutes
  • Market Research and Consulting Firms
  • Regulatory Agencies
  • Venture Capitalists
  • Government Organizations
  • Industry Associations and Professional Societies
  • Diagnostic companies

Report Objectives

  • To define, describe, segment, and forecast the spatial genomics & transcriptomics market based on offering, technique, application, type (service), end user (product), end user (service), and region
  • To provide detailed information about the factors influencing market growth, such as drivers, restraints, opportunities, and challenges
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall gene editing market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments concerning six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.
  • To strategically profile the key players in the global spatial genomics & transcriptomics market and comprehensively analyze their core competencies2 and market rankings.
  • To track and analyze competitive developments, such as product & service launches, acquisitions, collaborations, expansions, and partnerships in the gene editing market.
  • To profile the key players in the global spatial genomics & transcriptomics market and comprehensively analyze their product and services portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the spatial genomics & transcriptomics market
  • To benchmark players within the spatial genomics & transcriptomics market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy.

Previous Versions of this Report

Spatial Genomics & Transcriptomics Market by Technique (Spatial Transcriptomics, Spatial Genomics), Product (Instruments, Consumables, Software), Application (Translational Research, Drug Discovery), End User, Global Forecast to 2027

Report Code BT 7790
Published in Dec, 2022, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Spatial Genomics & Transcriptomics Market

DMCA.com Protection Status